UK-headquartered drug major GlaxoSmithKline has joined in supporting the US Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention's (CDC) first National Influenza Vaccination Week, taking place November 27-December 3. Throughout the period, the HHS and CDC will be reminding Americans of the importance of receiving an annual flu shot, while highlighting the increased availability of supply from previous years. Importantly, the agencies will also be raising awareness that seasonal influenza typically does not peak until February or later, so it's not too late to get vaccinated.
By the end of the month, GSK plans to ship most of the approximately 25 million doses of Fluarix and FluLaval (influenza virus vaccines) that it will bring to the USA this flu season. The company plans to substantially increase its flu manufacturing capacity and to continue to expand its portfolio in the coming years.
Each year, more than 200,000 Americans are hospitalized and approximately 36,000 die from flu-related complications. Getting the flu vaccination every year is the single best way to protect yourself and the ones you love from the flu, says GSK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze